Restricted accessResearch articleFirst published online 2012-07
Stem Cell Factor-Displaying Simian Immunodeficiency Viral Vectors Together with a Low Conditioning Regimen Allow for Long-Term Engraftment of Gene-Marked Autologous Hematopoietic Stem Cells in Macaques
Although clinical benefits have been reported in several human hematopoietic gene therapy trials, a remaining important goal is the transition to nonmyeloablative pretransplantation conditioning to decrease toxicity. Previous attempts at reduced intensity conditioning in nonhuman primates have resulted in only temporary vector marking of autologous blood cells or their persistence at low levels, well below the thresholds for clinical efficacy. In addition, we reasoned that lentiviral vector particles displaying cytokines at their surface have the potential to preserve stem cell fitness better than current ex vivo transduction protocols, which involve exposure to cytokine overstimulation. Here we show that the classically nonmyeloablative agent fludarabine (30 mg/m2/day for 3 days) together with low-level total body irradiation (2 Gy) and the use of a stem cell factor-displaying simian immunodeficiency virus-based vector, resulted in sustained, single-copy vector marking of autologous blood cells in two macaques over 3 years posttransplantation at levels averaging 1% of all lineages. This percentage is within the range of anticipated efficacy levels for hemophilia and related diseases and forms a basis for further improvement.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., SlavinS., AkerM.et al.2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296:2410–2413.
2.
BesnierC., TakeuchiY., TowersG.2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U.S.A., 99:11920–11925.
3.
BrennerS., RyserM., ChoiU.et al.2006. Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells. Mol. Ther., 14:202–211.
4.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C.et al.2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.
5.
Cavazzana-CalvoM., Hacein-BeyS., De Saint BasileG.et al.2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288:669–672.
6.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–322.
7.
DerdouchS., GayW., NègreD.et al.2008. Reconstitution of the myeloid and lymphoid compartments after the transplantation of autologous and genetically modified CD34+ bone marrow cells, following γ irradiation in cynomolgus macaques. Retrovirology, 5:50.
8.
FrechaC., CostaC., NegreD.et al.2008. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood, 112:4843–4852.
9.
GlimmH., OhI.H., EavesC.J.2000. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G2/M transit and do not reenter G0. Blood, 96:4185–4193.
10.
GoodmanE.R., FiedorP.S., FeinS.et al.1996. Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am. Surg., 62:435–442.
11.
GregoireV., HunterN., MilasL.et al.1994. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res., 54:468–474.
12.
GregoireV., BeauduinM., BruniauxM.et al.1998. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int. J. Radiat. Biol., 73:511–520.
13.
GreverM., LeibyJ., KrautE.et al.1990. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol., 17:39–48.
14.
Hacein-Bey-AbinaS., Le DeistF., CarlierF.et al.2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med., 346:1185–1193.
15.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM.et al.2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.
16.
HanawaH.2004. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood, 103:4062–4069.
17.
HayakawaJ., UedaT., LisowskiL.et al.2009. Transient in vivo β-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Hum. Gene Ther., 20:563–572.
18.
HemattiP., HongB.-K., FergusonC.et al.2004. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol., 2:e423.
19.
HentschkeP., BarkholtL., UzunelM.et al.2003. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant., 31:253–261.
20.
HornP.A., MorrisJ.C., BukovskyA.A.et al.2002. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther., 9:1464–1471.
21.
JetmoreA., PlettP.A., TongX.et al.2002. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34+ cells transplanted into conditioned NOD/SCID recipients. Blood, 99:1585–1593.
22.
KahlC.A., TarantalA.F., LeeC.I.et al.2006. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp. Hematol., 34:369–381.
23.
KangE.M., HanazanoY., FrareP.et al.2001. Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the Fanconi anemia C gene after conditioning with low-dose irradiation. Mol. Ther., 3:911–919.
24.
KangE.M., HsiehM.M., MetzgerM.et al.2006. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Experimental Hematology, 34:132–139.
25.
KeatingM.J., O'BrienS., RobertsonL.E.et al.1994. The expanding role of fludarabine in hematologic malignancies. Leuk. Lymphoma, 14,Suppl. 2:11–16.
26.
KellyP.F., RadtkeS., KalleC.V.et al.2007. Stem cell collection and gene transfer in Fanconi anemia. Mol. Ther., 15:211–219.
27.
KimY.J., KimY.S., LarochelleA.et al.2009. Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. Blood, 113:5434–5443.
28.
KorinY.D., ZackJ.A.1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol., 72:3161–3168.
29.
KungS.K., AnD.S., BonifacinoA.et al.2003. Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. Mol. Ther., 8:981–991.
30.
LiuJ., LiK., YuenP.M.et al.1999. Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow. Bone Marrow Transplant., 24:247–252.
31.
MangeotP.2002. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol. Ther., 5:283–290.
32.
MangeotP.E., NegreD., DuboisB.et al.2000. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J. Virol., 74:8307–8315.
33.
MauriceM.2002. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood, 99:2342–2350.
34.
MitsuyasuR.T., MeriganT.C., CarrA.et al.2009. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med., 15:285–292.
35.
MorrisJ.C.2004. Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood, 103:492–499.
36.
NegreD., MangeotP.E., DuisitG.et al.2000. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther., 7:1613–1623.
37.
OttM.G., SchmidtM., SchwarzwaelderK.et al.2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12:401–409.
38.
PlunkettW., GandhiV., HuangP.et al.1993. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin. Oncol., 20:2–12.
39.
RosenzweigM.2001. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood, 97:1951–1959.
40.
RothD.A., TawaN.E.Jr., O'BrienJ.M.et al.2001. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N. Engl. J. Med., 344:1735–1742.
41.
SandrinV.2002. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood, 100:823–832.
42.
SeggewissR., PittalugaS., AdlerR.L.et al.2006. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood, 107:3865–3867.
43.
ShimoniA., HardanI., AyukF.et al.2010. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer, 116:3621–3630.
44.
SteinS., OttM.G., Schultze-StrasserS.et al.2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.
45.
StoddartC.A., TrobridgeG.D., WuR.A.et al.2009. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One, 4:e7693.
46.
StoyeJ.P.2002. An intracellular block to primate lentivirus replication. Proc. Natl. Acad. Sci. U.S.A., 99:11549–11551.
47.
SuttonR.E., ReitsmaM.J., UchidaN., BrownP.O.1999. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J. Virol., 73:3649–3660.
48.
SwainsonL., VerhoeyenE., CossetF.L., TaylorN.2006. IL-7Rα gene expression is inversely correlated with cell cycle progression in IL-7-stimulated T lymphocytes. J. Immunol., 176:6702–6708.
49.
ThakarM.S., KurreP., StorbR.et al.2010. Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant., 46:539–544.
50.
TisdaleJ.F., HanazonoY., SellersS.E.et al.1998. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood, 92:1131–1141.
51.
TrobridgeG.D., BeardB.C., GoochC.et al.2008. Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood, 111:5537–5543.
52.
van den OudenrijnS., von dem BorneA.E., de HaasM.2000. Differences in megakaryocyte expansion potential between CD34+ stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp. Hematol., 28:1054–1061.
53.
VerhoeyenE., WiznerowiczM., OlivierD.et al.2005. Novel lentiviral vectors displaying “early-acting cytokines” selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood, 106:3386–3395.
54.
Von HoffD.D.1990. Phase I clinical trials with fludarabine phosphate. Semin. Oncol., 17:33–38.
55.
WoodsN.B.2002. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: Risk of insertional mutagenesis. Blood, 101:1284–1289.
56.
ZhangF., FrostA.R., BlundellM.P.et al.2010. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol. Ther., 18:1640–1649.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
